Shares of Financial Engines (FNGN) are making a comeback after a sharp summer selloff. Lamar Villere, portfolio manager for the Villere Balanced Fund (VILLX), said the retirement advisory company is back on track after its purchase of the Mutual Fund Store and Street-beating third quarter earnings report. 'Financial Engines is already very active in the 401k space, this is going to enable them to also participate in the IRA and other investment areas,' said Villere. 'I think there are going to be some cross-sell opportunities that will really add a lot to the story over the long term.' Shares of Financial Engines (FNGN) are down 6% so far this year. The Villere Balanced Fund (VILLX) is down slightly over 2% so far in 2015, according to fund-tracker Morningstar. Villere is also bullish on shares of Taser (TASR), which are down almost 30% year-to-date. He said the company will benefit from its body-camera business, even though it is currently spending a lot to bring it up to speed. 'The revenues in the body-camera business are growing at over 100% a year, we think that’s where the long term prospects are and right now we think investors have a zero value for that business and we think that’s a great place to invest,' said Villere. Villere is positive on Flowers Foods (FLO), up 39% year-to-date, and says the baker’s stock has more room to run even though it trades at a pricey 24 times next year’s earnings. 'They are growing organically, and coincidentally, they just bought a pair of organic bread-makers that are going to help them continue to grow,' said Villere. Finally, Villere is a fan of Howard Hughes Corp. (HHC), which has seen its stock drop almost 2% thus far in 2015. He said the real estate company will make a comeback after it saw low oil prices depress its property values in Texas.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.